CELLECTAR BIOSCIENCES, INC.

Analyst Reco. Cellectar Biosciences, Inc.

Equities

CLRB

US15117F8077

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
3.25 ^USD	+2.85%		+2.20%	+17.33%

May. 14	Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 14	Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating	Mar. 28	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating	Mar. 28	MT
Oppenheimer Boosts Price Target on Cellectar Biosciences to $11 From $8, Maintains Outperform Rating	Jan. 09	MT
Investors lower their expectations	Jan. 08
Oppenheimer Cuts Cellectar Biosciences Price Target to $8 From $10, Maintains Outperform Rating	23-09-11	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $10 From $11, Maintains Outperform Rating	23-05-05	MT
HC Wainwright Adjusts Price Target on Cellectar Biosciences to $4 From $30, Maintains Buy Rating	22-11-04	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $47, Maintains Outperform Rating	22-11-04	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $47 From $5.50, Maintains Outperform Rating	22-08-08	MT
Maxim Group Adjusts Cellectar Biosciences Price Target to $2 From $3, Maintains Buy Rating	22-02-02	MT
Cellectar Biosciences : Says Data From Trial Show 16.7% Complete Response Rate in Rare Blood Cancer Patients; Shares Down	21-06-04	MT
CELLECTAR BIOSCIENCES : Oppenheimer Adjusts Cellectar Biosciences' Price Target to $5.50 From $5, Maintains Outperform Rating	20-12-28	MT
Cellectar Biosciences, Inc. Reports Positive Top-Line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of Clr 131	19-02-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW